RecruitingNCT06858332

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Sponsor

Novartis Pharmaceuticals

Enrollment

2,382 participants

Start Date

Apr 15, 2025

Study Type

OBSERVATIONAL

Conditions

Atherosclerotic Cardiovascular Disease

Summary

This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Alirocumab, a drug called Atorvastatin, and others for people with atherosclerotic cardiovascular disease. The study is currently recruiting participants at 20 locations. People eligible for this study include aged 18 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAtorvastatin

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)

DRUGSimvastatin

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)

DRUGRozuvastatin

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)

DRUGEzetimibe

Ezetimibe

DRUGNiacin

Niacin

DRUGCiprofibrate

Fibrates

DRUGFenofibrate

Fibrates

DRUGBezafibrate

Fibrates

DRUGEvolocumab

PCSK9 inhibitor

DRUGAlirocumab

PCSK9 inhibitor

DRUGInclisiran

Small interfering RNA

Locations(20)

Novartis Investigative Site

Chelyabinsk, Russia

Novartis Investigative Site

Chelyabinsk, Russia

Novartis Investigative Site

Kaluga, Russia

Novartis Investigative Site

Kemerovo, Russia

Novartis Investigative Site

Krasnoyarsk, Russia

Novartis Investigative Site

Moscow, Russia

Novartis Investigative Site

Moscow, Russia

Novartis Investigative Site

Moscow, Russia

Novartis Investigative Site

Omsk, Russia

Novartis Investigative Site

Perm, Russia

Novartis Investigative Site

Ryazan, Russia

Novartis Investigative Site

Surgut, Russia

Novartis Investigative Site

Tomsk, Russia

Novartis Investigative Site

Tyumen, Russia

Novartis Investigative Site

Vladimir, Russia

Novartis Investigative Site

Vladivostok, Russia

Novartis Investigative Site

Voronezh, Russia

Novartis Investigative Site

Yakutsk, Russia

Novartis Investigative Site

Yekaterinburg, Russia

Novartis Investigative Site

Yekaterinburg, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06858332

Related Trials

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433782 locations

A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab

NCT075437311 location

Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial

NCT057058041 location

Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort

NCT068133391 location

Pelacarsen Roll-over Extension Program

NCT0687597397 locations